IL3 CAR T-cells

IL-3 CAR T-cells are a form of chimeric antigen receptor (CAR) T cell therapy engineered to express a receptor that targets the interleukin-3 (IL-3) binding domain, typically designed to recognize and attack acute myeloid leukemia (AML) cells. These modified T cells are developed to enhance specificity for AML by targeting antigens such as CD123, which is highly expressed on AML blasts but less so on normal hematopoietic stem cells. The mechanism of action involves genetic modification of patient or donor-derived T lymphocytes to express an artificial receptor that binds specifically to the target antigen, leading to activation and cytotoxic destruction of malignant cells upon engagement. Research into IL-3 CAR constructs has included strategies such as dual-CAR approaches combining IL-3-based targeting with costimulatory domains like CD33 in order to improve efficacy while minimizing off-target toxicity[1][5]. This therapy remains investigational and is primarily being studied in preclinical models and early-phase clinical trials for relapsed or refractory AML.

Other names

IL-3 CAR T cellsIL3 CAR T cellsIL 3 CAR T cellsInterleukin-3 chimeric antigen receptor T cellsInterleukin3 chimeric antigen receptor T cellsInterleukin 3 chimeric antigen receptor T cells